Athenex Inc. (ATNX)
0.20
-0.00 (-1.53%)
At close: May 24, 2023, 8:00 PM
-1.53% (1D)
| Bid | n/a |
| Market Cap | 2.33M |
| Revenue (ttm) | 119.83M |
| Net Income (ttm) | -102.89M |
| EPS (ttm) | -10.45 |
| PE Ratio (ttm) | -0.019435406698564594 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 1,754,889 |
| Avg. Volume (20D) | 263,314 |
| Open | 0.22 |
| Previous Close | 0.20 |
| Day's Range | 0.20 - 0.20 |
| 52-Week Range | 0.08 - 23.80 |
| Beta | 1.35 |
About ATNX
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clin...
Sector Healthcare
IPO Date Jun 14, 2017
Employees 269
Stock Exchange NASDAQ
Ticker Symbol ATNX
Website https://www.athenex.com